The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2016

Filed:

Feb. 02, 2016
Applicant:

Alexion Pharmaceuticals, Inc., Cheshire, CT (US);

Inventors:

Susan Faas McKnight, Old Lyme, CT (US);

Roxanne Cofiell, Glastonbury, CT (US);

Anjli Kukreja, Fairfield, CT (US);

Krystin A. Bedard;

Yan Yan, Cheshire, CT (US);

Assignee:

Alexion Pharmaceuticals, Inc., New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); G01N 2333/4716 (2013.01); G01N 2333/485 (2013.01); G01N 2333/522 (2013.01); G01N 2333/545 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/5421 (2013.01); G01N 2333/5434 (2013.01); G01N 2333/57 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70525 (2013.01); G01N 2333/70539 (2013.01); G01N 2333/7151 (2013.01); G01N 2333/7452 (2013.01); G01N 2333/75 (2013.01); G01N 2333/775 (2013.01); G01N 2333/8139 (2013.01); G01N 2333/8146 (2013.01); G01N 2333/974 (2013.01); G01N 2800/226 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.


Find Patent Forward Citations

Loading…